2-去(乙酰基甲基氨基)-15-甲氧基-2-甲基-美登素 | 117860-08-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酰胺类
• 中文名称: 2-去(乙酰基甲基氨基)-15-甲氧基-2-甲基-美登素
• 英文名称: 15-Methoxyansamitocin P-3
• 英文别名: [(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,15,20-trimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] 2-methylpropanoate
• CAS: 117860-08-9
• 化学式: C₃₃H₄₅ClN₂O₁₀
• 分子量: 665.2
• InChiKey: HCVXCBYLIZAAEV-XXGGWIJGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  46
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  145
• 氢给体数：
  2
• 氢受体数：
  10

文献信息

• [EN] DRUG-PROTEIN CONJUGATES<br/>[FR] CONJUGUÉS MÉDICAMENT-PROTÉINE
  申请人：POLYTHERICS LTD

  公开号：WO2014064423A1

  公开（公告）日：2014-05-01

  Specific conjugates containing auristatins and a binding protein or peptide, and processes for making them, are described. The conjugates use specific linker technology which gives advantages over known antibody-drug conjugates. Also described are specific conjugates of drugs and a binding protein or peptide in which more than one copy of the drug is present.

  包含奥利司他汀和结合蛋白或肽的特定共轭物以及制备它们的过程被描述。这些共轭物使用特定的连接技术，相比已知的抗体药物共轭物具有优势。还描述了药物和结合蛋白或肽的特定共轭物，其中药物的副本超过一个。
• DRUG-PROTEIN CONJUGATES
  申请人：POLYTHERICS LIMITED

  公开号：US20150290342A1

  公开（公告）日：2015-10-15

  Specific conjugates containing auristatins and a binding protein or peptide, and processes for making them, are described. The conjugates use specific linker technology which gives advantages over known antibody-drug conjugates. Also described are specific conjugates of drugs and a binding protein or peptide in which more than one copy of the drug is present.

  本发明涉及含有奥利司他汀和结合蛋白或肽的特定共轭物，以及制备它们的过程。这些共轭物使用特定的连接技术，比已知的抗体药物共轭物具有优势。本发明还描述了药物和结合蛋白或肽的特定共轭物，其中药物的副本超过一个。
• ANTIBODIES, ANTIBODY DRUG CONJUGATES AND METHODS OF USE
  申请人：GAMAMABS PHARMA

  公开号：US20170035903A1

  公开（公告）日：2017-02-09

  This invention relates to antibody drug conjugates (ADC), antibody conjugates (AC) and novel antibodies. Particularly, the ADC, AC and antibodies disclosed herein specifically bind to the human anti-Müllerian hormone type II receptor (AMHR-II) and can be used to treat and/or identify AMHR-II expressing cancers, such as prostate cancer, breast cancer and gynecologic cancers expressing AMHR-II, such as ovarian cancer, in particular metastatic ovarian cancer, serous cancer, hypernephroma, endometrioid, colloidal epithelium, prostate cancer, germ cell cancer, endometrial cancer, mixed Müllerian malignant tumor of the uterus, leiomyosarcoma, or endometrial stromal sarcoma.
• [EN] DRUG-PROTEIN CONJUGATES<br/>[FR] CONJUGUÉS MÉDICAMENTS-PROTÉINES
  申请人：POLYTHERICS LTD

  公开号：WO2014064424A1

  公开（公告）日：2014-05-01

  Specific conjugates containing maytansines and a binding protein or peptide, and processes for making them, are described. The conjugates use specific linker technology which gives advantages over known antibody-drug conjugates.